NCT07535554招募中2 期
Prospective Diagnostic Performance of PET/CT Using the Novel Fibroblast Imaging Tracer [18F]-AlF-FAPI-74 Versus Standard of Care [18F]-FDG in Inflammatory Disorders
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 140
- 试验地点
- 1
- 主要终点
- FUO/IUO: Demonstrate that the diagnostic performance of [18F]AlF-FAPI-74 PET/CT is equivalent or superior to the current gold standard, [18F] FDG PET/CT, in contributing to the final diagnosis (non-inferiority study with non-inferiority limit (10%)
研究概览
简要总结
The aim of the study to evaluate the performance of new [18F]-AlF-FAPI-74 PET/CT in three inflammatory disorders (fever of unknown origin, IgG4-related disease and axial spondyloarthritis) and compare with the current stand-of-care [18F]-FDG PET/CT
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •An illness of more than 3 weeks' duration,
- •Temperature exceeding 38.3°C on > 3 occasions, or elevated inflammatory markers on > 3 occasions
- •Diagnosis uncertain despite appropriate first-line investigations.
- •Inclusion criteria IgG4-RD:
- •High clinical suspicion of IgG4-RD by an experienced clinician of Internal Medicine, based on anamnesis, physical examination, first-line investigations and blood tests.
- •Patients with a new diagnosis of IgG4-RD on histopathology and need for further assessment of disease extent with PET/CT,
- •Relapse of diagnosed IgG4-RD on histopathology according to an experienced clinician of Internal Medicine
- •Inclusion criteria AxSpA:
- •High clinical suspicion of axial spondyloarthropahy according to an experienced rheumatology (based on inflammary back pain > 3 months, insidious onset, morning stifness, improvement with exercise and worsening in rest, pain worse at night, age at onset <45 years of age, imaging findings).
- •Patient has persisting inflammatory back pain after 2 different types of NSAID's (tried for over 2-4 weeks), and is therefore eligible for biological DMARDS therapy.
排除标准
- •Participant is mentally or legally incapacitated, doesn't understand the study design or is not willing or capable to undergo all study-specific procedures.
- •Any disorder or condition, which in the Investigator's opinion might jeopardise the participant's safety or compliance with the protocol.
- •Any prior or concomitant treatment(s) that might jeopardise the participant's safety or that would compromise the integrity of the Trial.
- •Female who is pregnant (urinary hCG test will be performed in every WOCBP), breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate, highly effective contraceptive (with a relatively high Pearl Index: natural methods, minipill outside postpartum period, spermicides or condoms in monotherapy or no usage of contraception when sexually active are not accepted).
- •Participation in an interventional Trial with an investigational medicinal product (IMP) or device when the trial designs are not considered compatible by the study team.
- •Participation in a clinical scientific study in the last 12 months with a radiation exposure caused by the experimental procedures greater than 1 mSv.
- •Participant has a known hypersensitivity to [18F]AlF-FAPI-74 or the used excipients.
- •Active treatment has already commenced
研究组 & 干预措施
FUO/IUO
Experimental
干预措施: [18F]AlF-FAPI-74 PET/CT (Diagnostic Test)
IgG4-related disease
Experimental
干预措施: [18F]AlF-FAPI-74 PET/CT (Diagnostic Test)
Axial Spondyloarthritis
Experimental
干预措施: [18F]AlF-FAPI-74 PET/CT (Diagnostic Test)
结局指标
主要结局
FUO/IUO: Demonstrate that the diagnostic performance of [18F]AlF-FAPI-74 PET/CT is equivalent or superior to the current gold standard, [18F] FDG PET/CT, in contributing to the final diagnosis (non-inferiority study with non-inferiority limit (10%)
时间窗: 6 months after completion of both PET/CT scans
IgG4-RD: Demonstrate that the diagnostic performance of [18F]AlF-FAPI-74 PET/CT is superior to [18F]FDG PET/CT, in patients with suspicion of IgG4-RD and assessment of disease extent in patients with confirmed or relapsed IgG4-RD.
时间窗: After completion of both PET/CT scans before initiation of treatment and after completion of both PET/CT scans 3 months completion of treatment.
Axial Spondyloarthritis: evaluate the diagnostic accuracy of [18F]AlF-FAPI-74 PET/CT in differentiating inflammatory back pain in patients with axSpA from patients with mechanical back pain, and evaluate the ability to assess treatment response
时间窗: After completion of first PET/CT scan and after completion of PET/CT scan performed 3 months after treatment
次要结局
- FUO/IUO: Determine the distribution of the four major causal group in FUO/IUO (infectious, inflammatory, malignant, and miscellaneous) of both tracers and evaluate for which causal groups [18F]AlF-FAPI-74 PET/CT is superior to [18F]FDG PET/CT.(6 months after completion of all PET/CT scans)
- FUO/IUO: Evaluate for which entities [18F]AlF-FAPI-74 has the potential to outperform [18F]FDG PET/CT in lager patient cohorts.(6 months after completion of all PET/CT scans)
- FUO/IUO: Determine the ratio of true positives, true negatives, false positives, false negative, positive predictive value, and negative predictive value.(6 months after completion of all PET/CT scans)
- IgG4-RD: Semi-quantitative uptake measurements (maximal standardized uptake value (SUVmax), average SUV (SUVmean), peak SUV (SUVpeak) of lesions on [18F]AlF-FAPI-74 PET/CT and [18F]FDG PET/CT.(After completion of both PET/CT scans before initiation of treatment and after completion of both PET/CT scans 3 months completion of treatment.)
- IgG4-RD: Evaluate the organ detection ratio for every organ, defined as the percentage of patients with pathological uptake in that specific organ by each tracer for the total of number of patients with pathological uptake in that organ(After completion of both PET/CT scans before initiation of treatment and after completion of both PET/CT scans 3 months completion of treatment.)
- IgG4-RD: 4) Evaluate the total number of affected organs per patient for each tracer and calculate the difference for both tracers. Determine the total difference of affected organs between both tracers for all patients.(After completion of both PET/CT scans before initiation of treatment and after completion of both PET/CT scans 3 months completion of treatment.)
- IgG4-RD: Evaluate the treatment response of FAPI and FDG lesions by quantifying the change in SUVmax between baseline and post-therapy PET/CT scans.(After completion of both PET/CT scans before initiation of treatment and after completion of both PET/CT scans 3 months completion of treatment.)
- AxSpA: Semi-quantitative uptake measurements (maximal standardized uptake value (SUVmax), target-to-background (TBR)) of lesions in the spine and the sacro-iliac joints will be computed on [18F]AlF-FAPI-74 PET/CT in all patients(After completion of first PET/CT scan and after completion of PET/CT scan performed 3 months after treatment)
- AxSpA: Determine if there is a significant statistical difference (p<0.05) in semi-quantitative uptake measurements (SUVmax, TBR) between the two cohorts, and determine the optimal cut-off value.(After completion of first PET/CT scan and after completion of PET/CT scan performed 3 months after treatment)
- AxSPa: Assess treatment response by evaluating changes in semi-quantitative measurements (SUVmax, TBR) in patients with axSpA following 3 month treatment with bDMARDs.(After completion of first PET/CT scan and after completion of PET/CT scan performed 3 months after treatment)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
Clinical Application of Al18F-NOTA-FAPI-04 PET/CT or PET/MRI Imaging in Malignant Tumor,Cardiovascular or Immune DiseaseNCT07400224Peking Union Medical College Hospital600
招募中
2 期
PET/CT imaging with FAPI as a biomarker for the distinction between predominant active fibrotic and inflammatory phenotypes in patients with progressive pulmonary fibrosis.2023-503686-26-02St Antonius Hospital20
撤回
2 期
PET/CT imaging with FAPI as a biomarker for the distinction between predominant active fibrotic and inflammatory phenotypes in patients with progressive pulmonary fibrosis.2023-503686-26-00St Antonius Hospital20
招募中
2 期
The Expression of Fibroblast Activation Protein in Patients with Non-Small Cell Lung Cancer Patients2025-523965-97-00Turku University Hospital60
招募中
3 期
The effect of [18F]F-FAPI PET-CT on management in patients with potentially resectable biliary tract cancers: prospective multicenter study and cost-effectivity analysis.Cholangiocarcinoma2023-507938-24-00Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)81